Mineralys Therapeutics (MLYS US)

Mineralys Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics offers aldosterone synthase inhibitor (ASI) that we are initially developing for the treatment of patients with uncontrolled hypertension.